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Abstract
The topic of how cost-effectiveness information informs priority setting in healthcare  remains important 
to both policy and practice. This commentary considers the study carried out by Eckard and colleagues 
in Sweden. In it we distinguish between the conditions at national and local levels and put forward some 
recommendations for research into local priority setting in particular.
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Within these pages Eckard and colleagues (1) contribute to the growing evidence base on usage of economic evaluation in priority setting, adding 
a uniquely Swedish dimension to the qualitative explorations 
of the last few years. Their findings and conclusions appear 
to confirm the divergence in experience between decision-
making tiers: whilst on the one hand national guidance 
producing bodies seek to routinely incorporate economic 
evaluation into their activities and indeed many are now 
formally mandated to do so, on the other hand local decision-
makers are disinclined or else unable to do the same (2–4). 
However, Eckard and colleagues (1) also remind us that not 
all is rosy at the national level. Despite a positive headline 
finding, their study uncovers persistent deficits in the 
quality and relevance of the economic evidence obtained, 
as well as the expertise required for its interpretation and 
critique. Furthermore, their study hints at some unresolved 
questions of ethics and efficiency. For example, there are 
equity concerns raised when a decision-making body makes 
only selective recourse to cost-effectiveness as a criterion 
when due process might imply that the same criteria are 
applied in each instance. The authors note that only in cases 
where evidence of improved clinical effectiveness is lacking 
is the cost-effectiveness ‘hurdle’ invoked. This prioritising 
of clinical benefit over relatively cost-effectiveness arguably 
raises further concerns regarding efficiency: for example, in a 
context of economic constraint would this approach preclude 
adoption of new treatments with marginal clinical inferiority 
but vastly reduced costs? And if so, does this not lead to a 
unnecessarily high opportunity costs?
These limitations and challenges aside, there is clearly a gap 
between the experience of national bodies – in this case the 
Swedish National Board of Health and Welfare – and the 
meso level function, however this latter is configured within 
country systems, and we believe this divergence is worthy of 
further consideration. 
The concern in this commentary is not to advocate for 
either an increased or reduced role for economic analysis 
in coverage decision-making but rather to examine current 
patterns in usage and the apparent divergence between 
national and local tiers. Indeed we believe the language of 
‘barriers’ to greater usage is loaded with normative intent and 
therefore should be avoided (5). Eckard and colleagues make 
effective use of the accessibility-acceptability framework to 
categorise impediments to an economics-informed approach 
(6,7). In this context accessibility relates to the shortage of 
relevant analyses as well as lack of expertise in its interpretation 
and critique. Whilst well-resourced national bodies can take 
steps to address such shortfalls, local decision-makers rarely 
have the resources to do so. Furthermore, at the local level 
the complex and interactive nature of the decision-making 
environment makes economic analysis less acceptable to 
those involved and in this respect, little has changed since the 
early work of Rudolf Klein (8) who observed:
‘Priority setting is a complex interaction of multiple decisions 
at various levels in the organisation and constrained by 
history. There is no self-evident set of ethical principles or 
analytical tools to determine what decisions we should take 
at various levels, nor is there an obvious or easy way to 
resolve the clash of claims on resources.’
Far from reflecting a linear model of decision-making, 
much local priority setting is subject to multiple influencing 
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factors including political considerations, administrative 
imperatives, distributional concerns, societal opinion and 
so on. Perhaps unsurprisingly therefore decision-makers 
perceive recommendations from economic analyses to be 
difficult to implement. For example, budget holders operating 
within short-term budgeting cycles may be under pressure 
to contain cost over and above promoting efficiency or may 
experience difficulties redirecting resources across inflexible 
financial structures.
It is important to note that complexity and pluralism can be 
a feature of coverage decision-making at both national and 
local levels. However, along a number of dimensions these 
phenomena tend to be more pronounced for local bodies 
who are: likely to be working to less clearly demarcated aims 
and goals; likely to be grappling with budget implications 
and the implementation of their decisions and; likely to have 
participants that are more explicitly sectional – i.e. openly 
advocating on behalf of their respective organisations – 
whereas members of national bodies are more likely to be at 
least nominally committed to a non-partisan approach. In a 
UK setting, the relatively high levels of external scrutiny on 
national decision-makers (i.e. of the National Institute for 
Health and Care Excellence) also predisposes them towards 
the routine use of economic analysis as a means of justifying 
and defending their decisions (9) (Table 1). 
Overall, the literature suggests a growing realisation that 
interventions by health economists in the area of research 
utilisation have not always addressed the totality of such 
factors, and it seems that whilst difficulties in accessing and 
interpreting economic studies present a continued challenge 
for decision-makers, issues of acceptability are more critical 
and far-reaching in their implications. If greater application 
of health economics to priority setting is the aim – and we 
acknowledge that this is contested – it seems logical to 
devise strategies which address these aspects. However, 
this multiplicity of factors has yet to be met with a similar 
scope and range of potential responses which have tended 
to centre on questions of how research by health economists 
can be made more accessible to policy-makers by increasing 
resources, improving the means of communication with 
decision-makers, and providing decision-makers with 
training in interpreting health economics. However, the more 
challenging problems of acceptability have remained relatively 
unaddressed and in particular it is unclear how organisational 
and political factors are to be addressed. 
In this context, we would emphasize the importance of 
a sustained and rigorous examination of the congruence 
between economic evaluation and organisational mission 
and aims, links to budget flows and compatibility with 
performance measurement/accountability mechanisms. 
In this, we welcome Eckard and colleagues’ attention to 
institutional features of decision-making bodies and believe 
that this should be integral to any future analysis of economic 
evaluation usage in priority setting. We know from other 
areas of study that context can shape the use of evidence in 
organisational and policy decision-making. If the extent 
to which knowledge is used in practice depends at least to 
some extent on institutional receptiveness, we clearly need to 
understand the incentives, rewards and penalties that might 
affect priority setters’ inclination to adopt economic analysis 
into their decision-making (10). 
At the national level there has begun in recent times to 
be a sustained analysis of variation between guidance 
producing bodies especially with regards to the terms of 
their delegated responsibilities, and Eckard and colleagues 
offer a timely intervention into this literature. We believe 
analysis of how these features interact with aspects of wider 
context to produce varying levels of demand for economic 
analysis would be a fruitful line of future enquiry. Much 
of the existing research confines its respondent group to 
those formally involved in the decision-making process. We 
believe responses from a wider range of interested parties 
– the public, government, clinicians and so on – might 
enrich future understanding of what the place of economics 
is, and should be, in priority setting. At the local level, 
where the decision-making infrastructure is most complex, 
future studies might also benefit from a systems oriented 
approach. The tendency to focus on individual decision-
making units, whilst informative, leaves important elements 
of the wider environment unexamined thereby restricting 
the development of theories relating to the full range of 
determinants of behaviour. At the heart of the challenge for 
researchers and practitioners alike is therefore the need to 
more thoroughly recognise the contextual elements of the 
task in hand. 
Overall we contend that whilst the use of cost-effectiveness 
information by national bodies is in large part a matter of 
accessibility, at local levels it requires greater consideration 
of context and acceptability. The impetus behind the use of 
economic analyses in resource allocation decisions is the 
requirement for greater rationality in decision processes. This 
arguably contributes to greater openness and transparency, 
and so necessitates that the information on which decisions 
are based is accessible to a wide audience. This accessibility 
imperative presents challenges to the health economics 
discipline and its proponents. It also suggests the need 
Table 1. Institutional factors and incentives to employ cost-effectiveness  analysis (9)
Institutional variable Institutional form Incentives to use economic analysis
Stated aims and goals
Explicit and relatively simple Increased 
Poorly specified and/or complex and multi-dimensional Decreased 
Relationship to implementation
None/indirect Increased
Direct Decreased
Institutional affiliation of actors
Non-sectional Increased
Sectional Decreased
External scrutiny 
High levels Increased
Low levels Decreased
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for decision-makers to embrace an open and transparent 
approach – something which can be difficult in healthcare 
where services are valued so highly and losses are so keenly 
contested. Rousseau (11) explores the discrepancy between 
what we can know (the ‘evidence’) and what we need to know 
in order to make decisions, and the inevitable gap between the 
two. Therefore, even where a ‘rational’ approach is preferred, 
extra work is required to translate evidence into a decision. 
This deliberative component of priority setting is often poorly 
articulated and less transparent than the evidence-generating 
component. Attention therefore needs to be paid to how 
deliberation within national guidance producing bodies 
might be codified and made clear to everyone. Too often there 
is a lack of both clarity and consensus regarding the process 
of moving collectively from consideration of the evidence to 
reaching a determination.
Overall, then it seems that despite the successes reported by 
Eckard and colleagues it remains at times lonely at the top 
for those pursuing an economics-informed approach and it 
is hard to avoid getting stuck in the middle where complexity 
and resistance is most pronounced. If progress is to be made, 
there is more that all parties – including from research, policy 
and practice settings – can do to help. 
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